Blackman Jonathan, Stankeviciute Laura, Arenaza-Urquijo Eider M, Suárez-Calvet Marc, Sánchez-Benavides Gonzalo, Vilor-Tejedor Natalia, Iranzo Alejandro, Molinuevo José Luis, Gispert Juan Domingo, Coulthard Elizabeth, Grau-Rivera Oriol
North Bristol NHS Trust, Bristol BS10 5NB, UK.
Bristol Medical School, University of Bristol, Bristol BS8 1UD, UK.
Brain Commun. 2022 Nov 3;4(6):fcac257. doi: 10.1093/braincomms/fcac257. eCollection 2022.
Sleep abnormalities are prevalent in Alzheimer's disease, with sleep quality already impaired at its preclinical stage. Epidemiological and experimental data point to sleep abnormalities contributing to the risk of Alzheimer's disease. However, previous studies are limited by either a lack of Alzheimer's disease biomarkers, reduced sample size or cross-sectional design. Understanding if, when, and how poor sleep contributes to Alzheimer's disease progression is important so that therapies can be targeted to the right phase of the disease. Using the largest cohort to date, the European Prevention of Alzheimer's Dementia Longitudinal Cohort Study, we test the hypotheses that poor sleep is associated with core Alzheimer's disease CSF biomarkers cross-sectionally and predicts future increments of Alzheimer's disease pathology in people without identifiable symptoms of Alzheimer's disease at baseline. This study included 1168 adults aged over 50 years with CSF core Alzheimer's disease biomarkers (total tau, phosphorylated tau and amyloid-beta), cognitive performance, and sleep quality (Pittsburgh sleep quality index questionnaire) data. We used multivariate linear regressions to analyse associations between core Alzheimer's disease biomarkers and the following Pittsburgh sleep quality index measures: total score of sleep quality, binarized score (poor sleep categorized as Pittsburgh sleep quality index > 5), sleep latency, duration, efficiency and disturbance. On a subsample of 332 participants with CSF taken at baseline and after an average period of 1.5 years, we assessed the effect of baseline sleep quality on change in Alzheimer's disease biomarkers over time. Cross-sectional analyses revealed that poor sleep quality (Pittsburgh sleep quality index total > 5) was significantly associated with higher CSF t-tau; shorter sleep duration (<7 h) was associated with higher CSF p-tau and t-tau; and a higher degree of sleep disturbance (1-9 versus 0 and >9 versus 0) was associated with lower CSF amyloid-beta. Longitudinal analyses showed that greater sleep disturbances (1-9 versus 0 and >9 versus 0) were associated with a decrease in CSF Aβ42 over time. This study demonstrates that self-reported poor sleep quality is associated with greater Alzheimer's disease-related pathology in cognitively unimpaired individuals, with longitudinal results further strengthening the hypothesis that disrupted sleep may represent a risk factor for Alzheimer's disease. This highlights the need for future work to test the efficacy of preventive practices, designed to improve sleep at pre-symptomatic stages of disease, on reducing Alzheimer's disease pathology.
睡眠异常在阿尔茨海默病中很常见,在其临床前阶段睡眠质量就已受损。流行病学和实验数据表明,睡眠异常会增加患阿尔茨海默病的风险。然而,以往的研究存在局限性,要么缺乏阿尔茨海默病生物标志物,要么样本量减少,要么采用横断面设计。了解睡眠质量差是否、何时以及如何导致阿尔茨海默病进展很重要,这样治疗才能针对疾病的正确阶段。利用迄今为止最大的队列,即欧洲预防阿尔茨海默病痴呆纵向队列研究,我们检验了以下假设:睡眠质量差与阿尔茨海默病核心脑脊液生物标志物存在横断面关联,并能预测基线时无阿尔茨海默病明显症状的人群未来阿尔茨海默病病理的增加。这项研究纳入了1168名50岁以上的成年人,他们有脑脊液阿尔茨海默病核心生物标志物(总tau蛋白、磷酸化tau蛋白和淀粉样β蛋白)、认知表现和睡眠质量(匹兹堡睡眠质量指数问卷)数据。我们使用多元线性回归分析阿尔茨海默病核心生物标志物与以下匹兹堡睡眠质量指数指标之间的关联:睡眠质量总分、二分类评分(睡眠质量差定义为匹兹堡睡眠质量指数>5)、入睡潜伏期、睡眠时间、睡眠效率和睡眠干扰。在一个由332名参与者组成的子样本中,他们在基线时和平均1.5年后采集了脑脊液,我们评估了基线睡眠质量对阿尔茨海默病生物标志物随时间变化的影响。横断面分析显示,睡眠质量差(匹兹堡睡眠质量指数总分>5)与脑脊液总tau蛋白水平升高显著相关;睡眠时间短(<7小时)与脑脊液磷酸化tau蛋白和总tau蛋白水平升高相关;睡眠干扰程度较高(1 - 9分与0分相比,>9分与0分相比)与脑脊液淀粉样β蛋白水平较低相关。纵向分析表明,随着时间的推移,睡眠干扰程度较大(1 - 9分与0分相比,>9分与0分相比)与脑脊液Aβ42水平下降相关。这项研究表明,自我报告的睡眠质量差与认知未受损个体中更严重的阿尔茨海默病相关病理有关,纵向结果进一步强化了睡眠紊乱可能是阿尔茨海默病危险因素的假设。这凸显了未来工作的必要性,即测试旨在改善疾病症状前阶段睡眠的预防措施对减少阿尔茨海默病病理的疗效。